ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment

Schema of ABCB5+ dermal mesenchymal stem cell (MSC) (DSC) characteristics compared to bone marrow (BM) ‐MSCs. Potential mechanisms of superior skin homing of ABCB5+ DSCs for use in recessive dystrophic epidermolysis bullosa (RDEB) and regenerative medicine applications. Similarities in immunomodulatory capacity of ABCB5+ DSCs and BM‐MSCs are shown in the middle column including anti‐inflammator y M1 >  M2 macrophage skewing. AbstractRecessive dystrophic epidermolysis bullosa (RDEB) is a rare, incurable blistering skin disease caused by biallelic mutations in type VII collagen (C7). Advancements in treatment of RDEB have come from harnessing the immunomodulatory potential of mesenchymal stem cells (MSCs). Although human bone marrow ‐derived MSC (BM‐MSC) trials in RDEB demonstrate improvement in clinical severity, the mechanisms of MSC migration to and persistence in injured skin and their contributions to wound healing are not completely understood. A unique subset of MSCs expressing ATP‐binding cassette subfamily member 5 (ABCB5) resides in the reticular dermis and exhibits similar immunomodulatory characteristics to BM‐MSCs. Our work aimed to test the hypothesis that skin‐derived ABCB5+ dermal MSCs (DSCs) possess superior skin homing ability compared to BM‐MSCs in immunodeficient NOD‐scid IL2rgammanull (NSG) mice. Compared to BM ‐MSCs, peripherally injected ABCB5+ DSCs demonstrated superior homing and engraftment of wounds. Furthermore, ABCB5+ DS...
Source: Stem Cells - Category: Stem Cells Authors: Tags: Regenerative Medicine Source Type: research